Hribaschek Arndt, Ridwelski Karsten, Pross Matthias, Meyer Frank, Kuhn Roger, Halangk Walter, Boltze Carsten, Lippert Hans
Department of Surgery, University Hospital, D-39120 Magdeburg, Germany.
Oncol Rep. 2003 Nov-Dec;10(6):1793-8.
Following resection of colorectal carcinoma, a considerable local recurrence rate within the previous tumor bed or at the peritoneal site remains an unsolved problem. Currently, there are no established protocols for the treatment or prevention of peritoneal carcinomatosis. Taxol showed benefit in patients with advanced tumor growth, in particular, gynecological carcinomas. Taxol was used to test whether it can either prevent or treat peritoneal tumor growth derived from colon carcinoma. In rats divided in 3 groups, peritoneal carcinomatosis was induced by tumor cell transfer: Taxol (170 mg/m(2)) was given i). directly (group A); ii). on days 5, 10, 15 postoperatively (representing early administration; group B), or iii). as late intraperitoneal (i.p.) chemotherapy (15, 20, 25 days following surgery; aiming for reduction of a manifest peritoneal carcinomatosis; group C) into the abdominal cavity. Tumor growth was quantified by tumor weight of the greater omentum and the mesenteric site, number of detectable tumor lesions, occurrence of hepatic and pulmonary metastases and the amount of ascites. Taxol was highly effective in preventing or reducing i.p. tumor spread when the drug was given directly or within a short time interval after tumor cell implantation (groups A and B), whereas no significant antineoplastic potential was found in the treatment of an established peritoneal carcinomatosis. In conclusion, Taxol appears to be a promising chemotherapeutic agent to be investigated in further detail with possible potential for a later human phase-I trial in peritoneal carcinomatosis.
结直肠癌切除术后，在先前肿瘤床或腹膜部位出现相当高的局部复发率仍是一个未解决的问题。目前，尚无既定的治疗或预防腹膜癌的方案。紫杉醇对晚期肿瘤生长患者有益，尤其是妇科癌症患者。本研究使用紫杉醇来测试其是否能够预防或治疗源自结肠癌的腹膜肿瘤生长。将大鼠分为3组，通过肿瘤细胞转移诱导腹膜癌：紫杉醇（170mg/m²）以以下方式给药：i）. 直接给药（A组）；ii）. 在术后第5、10、15天给药（代表早期给药；B组），或iii）. 作为晚期腹腔内化疗（术后15、20、25天；旨在减轻明显的腹膜癌；C组）注入腹腔。通过大网膜和肠系膜部位的肿瘤重量、可检测到的肿瘤病灶数量、肝和肺转移的发生情况以及腹水量来量化肿瘤生长。当紫杉醇在肿瘤细胞植入后直接给药或在短时间间隔内给药时（A组和B组），其在预防或减少腹腔内肿瘤扩散方面非常有效，而在治疗已形成的腹膜癌时未发现明显的抗肿瘤潜力。总之，紫杉醇似乎是一种有前景的化疗药物，有待进一步详细研究，可能有潜力用于后续腹膜癌的人体I期试验。
